ACURATE neo2 TAVI achieves high success in severe bicuspid aortic stenosis, demonstrating strong 30-day safety and efficacy.

For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) ...

A high burden of heart valve diseases is driving its expansion. India’s transcatheter aortic valve replacement (TAVR) market ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research led by the University of Bristol ...

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research has found.

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.